This product is an oral hypoglycemic drug. Its mechanism of hypoglycemic effect is to inhibit the activity of a-glucosidase in the small intestinal wall cells, delay the degradation of ingested carbohydrates, and thus reduce postprandial blood sugar levels.

Rosuvastatin is a selective, competitive HMG-CoA reductase inhibitor that increases the number of liver LDL receptors on the cell surface, enhances the uptake and catabolism of LDL, and inhibits liver VLDL synthesis, thereby reducing the total number of VLDL and LDL particles. For patients with various hypercholesterolemia and dyslipidemia, rosuvastatin can reduce total cholesterol, LDL-C, ApoB, non-HDL-C levels, while reducing TG and increasing HDL-C levels.

Rosuvastatin is a selective, competitive HMG-CoA reductase inhibitor that increases the number of liver LDL receptors on the cell surface, enhances the uptake and catabolism of LDL, and inhibits liver VLDL synthesis, thereby reducing the total number of VLDL and LDL particles. For patients with various hypercholesterolemia and dyslipidemia, rosuvastatin can reduce total cholesterol, LDL-C, ApoB, non-HDL-C levels, while reducing TG and increasing HDL-C levels.

Carvedilol is a neurohumoral antagonist with multiple actions, including non-selective beta-blocking, alpha-blocking and antioxidant properties. The vasodilatory effect is a selective alpha1-adrenergic receptor blocking action. Carvedilol reduces peripheral resistance by vasodilation and inhibits the renin-angiotensin-aldosterone system by beta-blockade. Plasma renin activity is reduced and fluid retention rarely occurs. Carvedilol does not have the intrinsic sympathomimetic activity of propranolol and it has membrane stabilizing properties. Carvedilol is a racemic mixture of two stereoisomers. In animal models, both isomers have alpha-adrenergic receptor blocking properties. The beta-adrenergic receptor blocking effect is a non-selective beta1 and beta2 adrenergic receptor blocking effect, and its action is related to the levorotatory form of carvedilol. Carvedilol is a strong antioxidant and a strong reactive oxygen free radical scavenger. The antioxidant properties of carvedilol and its metabolites have been confirmed by in vivo and in vitro animal studies and in vitro various human cell studies.

Carvedilol is a neurohumoral antagonist with multiple actions, including non-selective beta-blocking, alpha-blocking and antioxidant properties. The vasodilatory effect is a selective alpha1-adrenergic receptor blocking action. Carvedilol reduces peripheral resistance by vasodilation and inhibits the renin-angiotensin-aldosterone system by beta-blockade. Plasma renin activity is reduced and fluid retention rarely occurs. Carvedilol does not have the intrinsic sympathomimetic activity of propranolol and it has membrane stabilizing properties. Carvedilol is a racemic mixture of two stereoisomers. In animal models, both isomers have alpha-adrenergic receptor blocking properties. The beta-adrenergic receptor blocking effect is a non-selective beta1 and beta2 adrenergic receptor blocking effect, and its action is related to the levorotatory form of carvedilol. Carvedilol is a strong antioxidant and a strong reactive oxygen free radical scavenger. The antioxidant properties of carvedilol and its metabolites have been confirmed by in vivo and in vitro animal studies and in vitro various human cell studies.